Attached files
file | filename |
---|---|
EX-99.1 - Jiangbo Pharmaceuticals, Inc. | v167251_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act 1934
Date of
Report (date of earliest event reported): November 17, 2009
JIANGBO
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in charter)
Florida
(State or
other jurisdiction of incorporation)
333-86347
|
65-1130026
|
|
(Commission
File Number)
|
(IRS
Employer Identification
No.)
|
Middle
Section, Longmao Street, Area A, Laiyang Waixiangxing Industrial
Park
|
Laiyang
City, Yantai, Shandong Province, People’s Republic of China
26520
|
(Address of principal executive offices and zip code)
(0086)535-7282997
(Registrant's
telephone number including area code)
GENESIS PHARMACEUTICALS ENTERPRISES,
INC.
(Registrant's
former name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of registrant under any of the following
provisions:
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
¨ Soliciting
material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR
240.14a-12(b))
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
2.02
|
Results
of Operations and Financial
Condition.
|
On
November 17, 2009, Jiangbo Pharmaceuticals, Inc. (the “Company”) issued a
press release and hosted a conference call during which the Company’s operating
results for the first quarter of 2010 ended September 30, 2009 was discussed. A
copy of the press release is attached hereto as Exhibit 99.1.
Item
9.01
|
Financial
Statements and Exhibits.
|
Exhibit No.
|
Description
|
|
99.1
|
Press
Release dated November 17,
2009.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
JIANGBO
PHARMACEUTICALS, INC.
|
|||
By:
|
/s/ Cao Wubo
|
||
Name:
Cao Wubo
|
|||
Title:
Chief Executive
Officer
|
Dated:
November 20, 2009